Skip to main content
SpringerLink
Log in

Cutaneous Manifestations Induced by Antidiabetic Treatment

  • Chapter
  • First Online:
Book cover Dermatology and Diabetes

  • 1234 Accesses

Abstract

The prevalence of diabetes in the world has been growing and, consequently, the pharmacological industry was forced to extend the availability of drugs in order to treat these patients. The present chapter provides a detailed description of the most predominant skin manifestations in diabetes patients, caused by hypoglycemic agents. For instructional purposes, a division is made into 3 groups: oral hypoglycemic agents, subcutaneous hypoglycemic agents and insulins. Although with the new therapeutics and the advent of new devices for insulin application the appearance of skin injuries could be reduced, it is essential to recognize them to conduct a suitable therapeutical approach. This chapter also contains mention of the new technologies related to diabetes for insulin administration and glycemic self-monitoring.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sola D, Rossi L, Schianca G, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840–8.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Santamaría VG, Barrios EG. Educación médica continua—manifestaciones cutáneas de la diabetes mellitus. Rev Cent Dermatol pascua. 2001;10(1).

    Google Scholar 

  3. Salem CB, Hmouda H, Slim R, et al. Rare case of metformin-induced leukocytoclastic vasculitis. Ann Pharmacother. 2006;40(9):1685–7.

    Article  PubMed  Google Scholar 

  4. Choudhary S, McLeod M, Torchia D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol. 2013;6(6):31.

    PubMed  PubMed Central  Google Scholar 

  5. Voore P, Odigwe C, Mirrakhimov AE, et al. DRESS syndrome following metformin administration: a case report and review of the literature. Am J Ther. 2016;23(6):e1970–3.

    Article  PubMed  Google Scholar 

  6. Ruiz M, Lombardo F. Hipoglucemiantes Orales. In: Ruiz M (Ed). Diabetes Mellitus, Cuarta edición. Akadia; 2011. p. 259–72.

    Google Scholar 

  7. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001;56:265–94.

    Article  CAS  PubMed  Google Scholar 

  8. Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002;62:1463–80.

    Article  CAS  PubMed  Google Scholar 

  9. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulinsensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 2003;52:173–80.

    Article  CAS  PubMed  Google Scholar 

  10. Tan KC, Chow WS, Tso AW, et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia. 2007;50:1819–25.

    Article  CAS  PubMed  Google Scholar 

  11. Hollander P. Safety profile of acarbose, an α-glucosidase inhibitor. Drugs. 1992;44(3):47–53.

    Article  PubMed  Google Scholar 

  12. Ruiz M, Lombardo F. Nuevos fármacos: incretinas. In: Ruiz M (Ed). Diabetes Mellitus, Cuarta edición. Akadia; 2011. p. 273–86.

    Google Scholar 

  13. Meier J, Gethmann A, Nauck M, et al. The glucagon–like–peptide–1 metabolite GLP–1 amide reduces postprandial glycemia independently of gastric emptying and insulin secretions in humans. Am J Physiol Endocrinol Metab. 2006;290:e1118–23.

    Article  CAS  PubMed  Google Scholar 

  14. European Medicines Agency. 2017. http://www.ema. europa.eu. Accessed Feb 2017.

  15. Bastuji Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case–control study. J Invest Dermatol. 2011;131(3):637–43.

    Article  CAS  PubMed  Google Scholar 

  16. Béné J, Jacobsoone A, Coupe P, et al. Bullous pemphigoid induced by vildagliptin: a report of three cases. Fundam Clin Pharmacol. 2014;29(1):112–4.

    Article  PubMed  Google Scholar 

  17. Murrel DF, Daniel BS, Joly P, et al. Definitions an outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66:479–85.

    Article  Google Scholar 

  18. Sundaram M, Adikrishnan S, Murugan S. Co-existence of rheumatoid arthritis, vitiligo and bullous pemphigoid as multiple autoinmune sindrome. Indian J Dermatol. 2014;59(3):306–7.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Unidad de fármacovigilancia del País Vasco. Inhibidores de la dipeptidil peptidasa 4 (gliptinas) y penfigoide ampollar. Boletín n°38, septiembre 2014.

    Google Scholar 

  20. Attaway A, Mersfelder T, Vaishnav S, et al. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatol Case Rep. 2014;8(1):24–8.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Skandalis K, Spirova M, Gaitanis G, et al. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase–IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26(2):249–53.

    Article  CAS  PubMed  Google Scholar 

  22. Mendonça FM, Martín-Gutierrez FJ, Ríos-Martín JJ, Camacho-Martinez F. Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors-one due to linagliptin. Dermatology. 2016;232(2):249–53.

    Article  PubMed  Google Scholar 

  23. Taharani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1:140–51.

    Article  Google Scholar 

  24. Leiter L. Symposium of safety and adverse effects. The role of SGLT2 inhibitors in the treatment of type 2 diabetes. 74th Congress American Diabetes Association. San Francisco, California; 2014.

    Google Scholar 

  25. De Fronzo RA, Davidson J, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;141(1):5–14.

    Article  Google Scholar 

  26. Vasapollo P, Cione E, Luciani F, Gallelli L. Generalized intense pruritus during canagliflozin treatment: Is it an adverse drug reaction? Curr Drug Saf. 2016.

    Google Scholar 

  27. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4:661–7.

    Article  PubMed  Google Scholar 

  28. Perez MI, Kohn SR. Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol. 1994;30:519–31.

    Article  CAS  PubMed  Google Scholar 

  29. Piérard-Franchimont C, Hermanns-Lê T, Scheen AJ, Piérard GE. Cutaneous complications of insulin therapy. A drug-induced condition on the decline. Rev Med Liege. 2005;60:564–5.

    PubMed  Google Scholar 

  30. Van Hattem S, Bootsma A, Bing Thio H. Skin manifestations of diabetes. Cleve Clin J Med. 2008;75:772–87.

    Article  PubMed  Google Scholar 

  31. Del Olmo MI, Campos V, Abellán P, et al. A case of lipoatrophy with insulin detemir. Diabetes Res Clin Pract. 2008;80:20–1.

    Article  Google Scholar 

  32. Saraceno EF. Manifestaciones Cutáneas del tratamiento Antidiabético. In: Cabo H, editor. Manifestaciones Cutáneas de la Diabetes Mellitus. Buenos Aires: Ed A. Macchi; 1996. p. 165–78.

    Google Scholar 

  33. Radermecker RP, Piérard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol. 2007;8:21–8.

    Article  PubMed  Google Scholar 

  34. Babiker A, Datta V. Lipoatrophy with insulin analogues in type I diabetes. Arch Dis Child. 2011;96:101–2.

    Article  PubMed  Google Scholar 

  35. Holstein A, Stege H, Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Expert Opin Drug Saf. 2010;9:225–31.

    Article  CAS  PubMed  Google Scholar 

  36. Andrade P, Barros L, Gonçalo M. Type 1 Ig-E mediated allergy to human insulin, insulin analogues and beta-lactam antibiotics. An Bras Dermatol. 2012;87(6):917–9.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Deiss D, Adolfsson P, Alkemade-van Zomeren M, et al. Insulin infusion set use: European perspectives and recommendations. Diabetes Technol Ther. 2016;18(9):517–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Commendatore, Víctor F, Linari M, Dieuzeide G, et al. Automonitoreo y Monitoreo de Glucosa y Cetonas en la persona con diabetes. Monografía en Internet. Buenos Aires: Sociedad Argentina de Diabetes; 2014.

    Google Scholar 

  39. American Diabetes Association. 6. Glycemic targets. Diabetes Care. 2017;40(Suppl.1):S48–56.

    Article  Google Scholar 

  40. Miracle López S, Barreda BF. Manifestaciones cutáneas de la diabetes mellitus, una manera clínica de identificar la enfermedad. Rev Endocrinol Nutr. 2005;13(2):75–87.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Division, Hospital de Clínicas José de San Martín, University of Buenos Aires (UBA), Buenos Aires, Argentina

    Marina Luz Margossian

  2. Dermatology Department, Instituto de Investigaciones Médicas A. Lanari, University of Buenos Aires (UBA), Buenos Aires, Argentina

    Emilia Noemí Cohen Sabban

Authors
  1. Marina Luz Margossian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emilia Noemí Cohen Sabban
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marina Luz Margossian .

Editor information

Editors and Affiliations

  1. Dermatology Department, Instituto de Investigaciones Médicas A. Lanari, University of Buenos Aires (UBA), Buenos Aires, Argentina

    Emilia Noemí Cohen Sabban

  2. Division of Diabetology, Department of Medicine, University of Buenos Aires, Buenos Aires, Argentina

    Félix Miguel Puchulu

  3. Division of Endocrinology, Diabetes and Metabolism, The University of Florida, Gainesville, Florida, USA

    Kenneth Cusi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Margossian, M.L., Sabban, E.N.C. (2018). Cutaneous Manifestations Induced by Antidiabetic Treatment. In: Cohen Sabban, E., Puchulu, F., Cusi, K. (eds) Dermatology and Diabetes. Springer, Cham. https://doi.org/10.1007/978-3-319-72475-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-72475-1_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-72474-4

  • Online ISBN: 978-3-319-72475-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation